Alembic , a prominent player in the Indian pharmaceutical sector, has received positive news from the U.S. Food and Drug Administration (USFDA) while also reporting strong financial performance in its latest quarterly results.

USFDA Clearance for Manufacturing Facilities

Alembic has announced the receipt of an Establishment Inspection Report (EIR) from the USFDA for its API-I and API-II facilities located in Panelav, Gujarat. This follows an inspection conducted between May 26-31. The EIR is a significant milestone, indicating that these manufacturing sites are in compliance with regulatory standards.

This recent clearance adds to the company's regulatory successes. In June, Alembic had previously received an EIR for its API-III facility at Karakhadi, following an inspection in March of the same year.

New Drug Approval

In a separate development, Alembic secured final USFDA approval for its Macitentan Tablets, 10 mg, a generic drug application, on August 19. This approval expands the company's portfolio in the U.S. market.

Strong Quarterly Performance

Alembic has reported robust financial results for the latest quarter:

The company's EBITDA margins showed improvement, increasing from 15.20% to 16.50% year-on-year.

Stock Performance

At the close of trading, Alembic's shares were priced at ₹945.40 on the National Stock Exchange (NSE), representing a marginal decline of 0.18%.

These developments, including regulatory clearances and strong financial performance, underscore Alembic's efforts to strengthen its position in both domestic and international markets.

Alembic Limited (ISIN: INE426A01027) has announced important dates for its shareholders regarding dividend payment and the upcoming Annual General Meeting (AGM) for the financial year 2020-21.

Book Closure Period

The company has declared that its Register of Members and Share Transfer Books will remain closed from July 31, 2021 to August 6, 2021, both dates inclusive. This closure period is crucial for determining the eligibility of shareholders for two key corporate actions:

1. Dividend Payment
2. Participation in the Annual General Meeting

Significance for Shareholders

This announcement is particularly important for Alembic Limited's shareholders as it determines:

• Dividend Eligibility: Shareholders on record as of the book closure dates will be eligible to receive the dividend for FY 2020-21.
• AGM Participation: The book closure will establish the list of members eligible to participate in the company's Annual General Meeting.

Key Dates to Remember

Shareholders and potential investors should take note of these dates, as they are critical for receiving dividends and exercising voting rights at the AGM.

Alembic Limited's decision to close its books for these corporate actions is a standard practice in corporate governance, ensuring a clear record of eligible shareholders for both dividend distribution and AGM participation.

Investors are advised to ensure that their shareholding details are up to date with their respective depository participants or with the company's registrar and transfer agent before the book closure period begins.